Rédaction Africa Links 24 with Sarah Jane Lebrasse
Published on 2024-03-28 14:00:41
The Apollo Cancer Centers group is ushering in a new era in healthcare with the launch of the first CyberKnife® S7™ FIM in South Asia. This revolutionary robotic radiotherapy system offers a novel treatment modality for both cancerous and non-cancerous tumors, marking a turning point in the fight against cancer in South Asia.
The CyberKnife® S7™ FIM, the very first of its kind in South Asia, represents a major advancement in cancer care. This non-invasive treatment is designed to target cancerous and non-cancerous tumors as well as other conditions requiring radiotherapy throughout the body, including the brain, lungs, spine, prostate, and abdominal cancers.
It serves as a promising alternative to surgery for patients with inoperable or surgically complex tumors. Even patients who have already undergone radiotherapy, have metastatic lesions, or have recurrent cancers can benefit from it.
Dr. Mahadev Potharaju, senior consultant in the radio-oncology department at Apollo Cancer Center, emphasizes that “CyberKnife® S7™ FIM treatments are typically performed in 1 to 5 sessions, each lasting 30 to 90 minutes. 100 to 200 radiation beams are delivered from different angles. Each beam lasts about 10 to 15 seconds. These non-invasive outpatient procedures, requiring no anesthesia or incisions, allow patients to resume their daily activities throughout the duration of the treatment.”
Dr. Ratnadevi R, senior consultant in the radio-oncology department, also adds that “CyberKnife S7 FIM is particularly effective in treating common benign brain lesions (shwannoma, meningioma, AVM) in a non-invasive manner, avoiding open surgery. It offers real-time and motion-synchronized adaptation for treating any mobile target, improving precision for mobile tumors in the lungs, liver, or prostate.”
Dr. Shankar Vangipuram, senior consultant in the radio-oncology department at Apollo Cancer Center, further states that “The CyberKnife® S7™ FIM system redefines the future of radiotherapy, combining speed, precision, and real-time target tracking, driven by AI Synchrony®. It offers precise hypofractionated SRS/SBRT treatments for an expanded range of indications. This includes benign brain tumors, brain metastases, certain medically refractory functional indications: trigeminal neuralgia, cluster headaches, tremors, lesion epilepsy, and some inoperable extra-cranial cancers (for medical or technical reasons) of the lungs, pancreas, liver, prostate, and recurrent head and neck cancers.”
The Apollo Cancer Centers group, a pioneer in the use of CyberKnife technology for 15 years, has successfully treated 3,000 cases from India and abroad. As the first center in South Asia to launch the latest generation CyberKnife® S7™ FIM, Apollo Cancer Centers sets a new standard in the region while continuing to demonstrate its commitment to innovation. Apollo Cancer Centers is the first in the country to be accredited to offer a certified training program in CyberKnife®.
Benefits for patients of CyberKnife® S7™ FIM:
– Precise, efficient, and targeted treatment allowing for a quick return to daily life.
– Improved quality of life for the patient with fewer treatment sessions.
– Long-term cancer control through a non-surgical and non-invasive outpatient procedure.
– Minimal dose to healthy tissues, reducing side effects.
– Greater patient comfort – the only technology that allows breathing freely during radiotherapy.
– Reduced risk of recurrence.
CyberKnife® S7™ FIM: State-of-the-art technology redefining cancer care in South Asia.
– High-precision robots, advanced imaging, and sophisticated software to provide extremely precise radiation anywhere in the body with submillimeter accuracy.
– An unparalleled approach to treating inoperable tumors, allowing for early patient recovery and significantly improving their quality of life.
The CyberKnife system:
It stands out as the only radiation treatment device with a linear accelerator directly mounted on a robot to administer high-energy X-rays or photons used in radiotherapy. With real-time image guidance and a robot, it delivers doses from thousands of beam angles, thus setting a new standard for precision delivery throughout the body.
#WinningOverCancer
About Apollo Cancer Centers – https://apollocancercentres.com/
For over 30 years, Apollo Cancer Centers has brought hope to the lives of thousands of people. With a network of over 325 oncologists across India, Apollo offers comprehensive 360-degree care, setting international standards for clinical outcomes. As the first pencil beam proton therapy center in South Asia and the Middle East, Apollo continues to play a key role in the global fight against cancer. Today, people from 147 countries come to India for cancer treatment at Apollo Cancer Centers.
Read the original article(French) on Le Mauricien
